Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now

FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic catheter, marking the company’s first regulatory approval in the US and a significant milestone in its commercial journey. This approval enables Imricor to begin commercial rollout of the catheter, and the market responded positively, with…

ByCharlie YouldenJanuary 12, 2026

Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum

Mesoblast Lifts on Ryoncil Growth Mesoblast (ASX:MSB) delivered a very strong performance this morning following a positive guidance update for Ryoncil, its cell-based therapy and the only FDA approved treatment for steroid refractory acute graft versus host disease. This is a serious and often life-threatening condition with limited treatment options, which helps explain the growing…

ByCharlie YouldenJanuary 9, 2026

Cochlear (ASX:COH) is still a long term growth story you should listen to

Cochlear is one of few stocks that has created immense shareholder value and has also greatly improved the lives of its users. Yes, this can be said with respect to many ASX health stocks, but this one can hang its hat on its societal impacts more than most other companies. What are the Best ASX Stocks…

ByNick SundichJanuary 9, 2026

Ansell (ASX:ANN) Drops 6% on CEO Exit: Is This a Buying Opportunity?

Is Ansell's CEO Change a Hidden Opportunity for Investors? Ansell (ASX: ANN) fell over 6% on Thursday after announcing that CEO Neil Salmon will retire, with the stock dropping to its lowest level in three months. Shares closed at A$33.38, down from A$35.58 the previous day. The news caught some investors off guard, triggering a…

ByUjjwal MaheshwariJanuary 9, 2026

Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$180bn company behind obesity drug Ozempic

Not many 100-year old healthcare stocks see a sudden 30% jump in sales in one year and become the largest capitalised company on their entire continent but Novo Nordisk (CPH: NOVO-B) is one such stock that did just that. Its a Danish drug maker that is behind weight loss drugs Ozempic and Wegovy. For much of…

ByNick SundichJanuary 8, 2026

Sonic Healthcare (ASX:SHL): Australia’s biggest pathology stock is available at a bargain price

It is not often that you can buy a blue-chip stock at a bargain price, but Sonic Healthcare (ASX:SHL) is such an opportunity. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] Introduction to Sonic Healthcare (ASX:SHL) Sonic Healthcare is a medical diagnostics company, headquartered in Sydney but with…

ByNick SundichJanuary 7, 2026

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

At Stocks Down Under, it has been a while since we've looked at Ozempic and other GLP-1 Drugs. Investors paid a lot of attention to them in 2023, particularly those invested in companies with potential to be impacted directly or indirectly. The industry has come a fair way in the past couple of years and…

ByNick SundichJanuary 6, 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead! What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] Stocks Down Under's Top 10 Hottest ASX Stocks to Look At in 2026! Note: These…

ByNick SundichJanuary 2, 2026

Monash IVF (ASX:MVF) Plunges 15% as $312m Takeover Bid Collapses- Is This a Buying Opportunity?

Monash IVF: Is This a Buying Opportunity? Monash IVF (ASX: MVF) shares crashed 15% to 69.5 cents last week after Soul Patts and Genesis Capital abruptly withdrew their A$312 million takeover bid. The consortium gave no explanation for walking away from the 80-cent offer that Monash's board had rejected as "opportunistic" just four weeks ago.…

ByUjjwal MaheshwariDecember 29, 2025

Our 5 ASX Predictions for 2026!

This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…

ByNick SundichDecember 24, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now

Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum

Cochlear (ASX:COH) is still a long term growth story you should listen to

Ansell (ASX:ANN) Drops 6% on CEO Exit: Is This a Buying Opportunity?

Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$180bn company behind obesity drug Ozempic

Sonic Healthcare (ASX:SHL): Australia’s biggest pathology stock is available at a bargain price

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Monash IVF (ASX:MVF) Plunges 15% as $312m Takeover Bid Collapses- Is This a Buying Opportunity?

Our 5 ASX Predictions for 2026!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here